Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Alemtuzumab (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SUPPRESS
- 12 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 26 Oct 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.
- 03 May 2017 New trial record